ITGA5 Predicts Dual-Drug Resistance to Temozolomide and Bevacizumab in Glioma

AIMS: Anti-angiotherapy (Bevacizumab) is currently regarded as a promising option for glioma patients who are resistant to temozolomide (TMZ) treatment. But ongoing clinical research failed to meet therapeutic expectations. This study aimed to explore the pivotal genetic feature responsible for TMZ...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Ying, Wu, Mengwan, Liu, Yuyang, Hu, Lanlin, Wu, Hong, Xie, Lei, Liu, Zhiwei, Wu, Anhua, Chen, Ling, Xu, Chuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719456/
https://www.ncbi.nlm.nih.gov/pubmed/34976814
http://dx.doi.org/10.3389/fonc.2021.769592

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719456/
https://www.ncbi.nlm.nih.gov/pubmed/34976814
http://dx.doi.org/10.3389/fonc.2021.769592

Ejemplares similares